Detailed Narrative
Q2 FY26 Financial Performance Overview
Aarti Pharmalabs reported a standalone top line of INR 417 crores for Q2 FY26, an 11% increase year-on-year from INR 377 crores. However, standalone EBITDA declined to INR 75 crores from INR 85 crores in the prior year, and PAT decreased to INR 31 crores from INR 48 crores. Consolidated figures showed a top line of INR 418 crores, EBITDA of INR 75 crores, and PAT of INR 28 crores, all lower than Q2 FY25. The PAT was significantly impacted by a Forex loss of approximately INR 7.4 crores during the quarter.
Segmental Performance and Margin Dynamics
The Xanthine Derivative segment contributed 51% to the Q2 turnover, with 71% from beverage customers and 59% from export sales. The API and Intermediates business accounted for 39% of turnover, facing high margin pressure and a sales mix skewed towards lower-margin products. The CDMO-CMO segment contributed 10% to revenue, working with 21 customers on 59 active projects, with 39 already in the commercial stage. Management noted that overall gross and EBITDA margins were affected by intermediate manufacturing for CDMO projects taking up capacity, genericization of older API products, and the Forex loss.
Strategic Projects and Capacity Expansion
The Atali plant was inaugurated in September 2025 and has commenced trial batches for customer qualifications. It is expected to be fully operational within two to three quarters, contributing meaningfully to revenue from FY27. The Xanthine expansion is progressing as planned, with current operations at 500 metric tons per month, aiming to reach an installed capacity of 9,000 metric tons per annum by the end of the current financial year. These expansions are designed to avoid impacting current running capacity.
Revised Guidance and Future Outlook
The company revised its full-year FY26 EBITDA growth guidance to 8% to 12% year-on-year. The CDMO-CMO segment is on track to exceed its earlier estimated sales growth target of 30% to 40% year-on-year. Management anticipates an improvement in the API business performance in the second half of FY26. For Ganesh Polychem, stabilization and reasonable profitability, near FY25 levels (80-100% of FY25 PAT), are expected from FY27 onwards after a period of shutdowns and cost reduction.
Capital Allocation and Debt Management
The Atali project involved a CAPEX of approximately INR 450 crores, adding 440 KL of capacity, with 340 KL already commercialized. The company's foreign currency long-term loans, amounting to 24 million USD, were kept open to save hedging costs, which led to the reported Forex loss due to rupee depreciation. Expenses related to the commercialized portion of the Atali plant are expected to start hitting the P&L from Q4 FY26, with a clearer impact of INR 4-5 crores per quarter anticipated.
CDMO Strategy and Pipeline Development
Aarti Pharmalabs is actively increasing its CDMO funnel by establishing a presence in Europe and planning to appoint a dedicated BD person for North America. The company focuses on Phase 2-3 molecules and aims to increase its wallet share with existing customers while also pursuing new products. The goal is to become a preferred source for innovators, ensuring supply chain security, although innovators typically maintain multiple sources.